

# Turkey

Population 2016

80 million

Estimates of TB burden*, 2016	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	0.48 (0.35–0.63)	0.61 (0.44–0.79)
Mortality (HIV+TB only)	0.015 (0.011–0.02)	0.02 (0.01–0.02)
Incidence (includes HIV+TB)	14 (12–16)	18 (15–20)
Incidence (HIV+TB only)	0.092 (0.077–0.11)	0.12 (0.1–0.14)
Incidence (MDR/RR-TB)**	0.56 (0.46–0.65)	0.7 (0.58–0.82)

Estimated TB incidence by age and sex (thousands)*, 2016			
	0-14 years	> 14 years	Total
Females	0.7 (0.6–0.81)	5.3 (4.5–6.1)	6 (5.1–6.9)
Males	0.79 (0.67–0.91)	7.2 (6.1–8.3)	8 (6.8–9.2)
Total	1.5 (1.3–1.7)	13 (11–14)	14 (12–16)

TB case notifications, 2016	
Total cases notified	12 417
Total new and relapse	12 186
- % tested with rapid diagnostics at time of diagnosis	
- % with known HIV status	70%
- % pulmonary	66%
- % bacteriologically confirmed among pulmonary	79%

Universal health coverage and social protection	
TB treatment coverage (notified/estimated incidence), 2016	87% (75–100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2016	0.04 (0.03–0.05)

TB/HIV care in new and relapse TB patients, 2016	Number	(%)
Patients with known HIV-status who are HIV-positive	56	<1%
- on antiretroviral therapy	51	91%

Drug-resistant TB care, 2016	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			350 (300–390)
Estimated % of TB cases with MDR/RR-TB	2.9% (2.5–3.4)	16% (13–19)	
% notified tested for rifampicin resistance	48%	62%	6 051
MDR/RR-TB cases tested for resistance to second-line drugs			162
Laboratory-confirmed cases		MDR/RR-TB: 256, XDR-TB: 9	
Patients started on treatment ****		MDR/RR-TB: 217, XDR-TB: 9	

Treatment success rate and cohort size	Success	Cohort
New and relapse cases registered in 2015	87%	12 362
Previously treated cases, excluding relapse, registered in 2015	46%	158
HIV-positive TB cases registered in 2015	58%	57
MDR/RR-TB cases started on second-line treatment in 2014	63%	257
XDR-TB cases started on second-line treatment in 2014	0%	2

TB preventive treatment, 2016	
% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	100% (100–100)

TB financing, 2017	
National TB budget (US\$ millions)	

\* Ranges represent uncertainty intervals


\*\* MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

\*\*\* Includes cases with unknown previous TB treatment history

\*\*\*\* Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed


## Tuberculosis profile

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence  
— Notified (new and relapse)  
— Incidence (HIV+TB only)

Notified cases by age group and sex, 2016



Treatment success rate (%)



— New and relapse  
— Retreatment, excluding relapse  
— HIV-positive — MDR/RR-TB — XDR-TB

Total budget (US\$ millions)

